Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 139 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacterial Sepsis Clear all
Completed Phase 1 Interventional

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

NCT00130221
View directory record Official record
Conditions
Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions
2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap
Drug · Other
Lead sponsor
Cook County Health
Government
Eligibility
16 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Clinical Decision Support Tool for Vancomycin Dosing in Children

NCT04911270
View directory record Official record
Conditions
Gram-Positive Bacterial Infections, Vancomycin, Pharmacokinetics, Pharmacodynamics
Interventions
Computer Decision Support Tool Intervention Group, Matched Historical Controls
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting No phase listed Observational

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

NCT01904188
View directory record Official record
Conditions
Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial, Infection, Fungal, Infection, Coronavirus, Antibiotic Resistance Genes, Human Genome Analysis
Interventions
Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)
Device
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2032
U.S. locations
2
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed No phase listed Observational

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

NCT02420366
View directory record Official record
Conditions
Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
Interventions
Not listed
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

NCT02439359
View directory record Official record
Conditions
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Interventions
CF-301, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Lenexa, Kansas • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

NCT00027248
View directory record Official record
Conditions
Sepsis, Bacteremia, Fungemia
Interventions
MBI 226
Drug
Lead sponsor
BioWest Therapeutics Inc
Industry
Eligibility
16 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Lake Bluff, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

NCT00815516
View directory record Official record
Conditions
Candidiasis
Interventions
micafungin, amphotericin B deoxycholate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
48 Hours to 120 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Orange, California • New Brunswick, New Jersey • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335
View directory record Official record
Conditions
Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

NCT00413218
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia, Mycoses
Interventions
Isavuconazole, Caspofungin, Voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 21, 2026, 9:30 PM EDT
Active, not recruiting No phase listed Observational

Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia

NCT05296590
View directory record Official record
Conditions
Bacteremia, Bacteremia Sepsis, Sepsis, Septic Shock, Severe Sepsis, Emergency Departments, Continuity of Patient Care
Interventions
Monocyte Distribution Width (MDW) , observation
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

NCT03148756
View directory record Official record
Conditions
Endocarditis, Bacteremia
Interventions
Dalbavancin, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ft. Pierce, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 4 Interventional Results available

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

NCT00841971
View directory record Official record
Conditions
Mycoses, Fungemia, Central Nervous System Fungal Infections, Lung Diseases, Fungal
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge

NCT07486362
View directory record Official record
Conditions
Bacteremia
Interventions
No Intervention
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed No phase listed Observational

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

NCT00414362
View directory record Official record
Conditions
Urinary Tract Infection, Fluoroquinolone, Bacteremia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated Not applicable Interventional Results available

S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT

NCT01312675
View directory record Official record
Conditions
Severe Sepsis
Interventions
S.A.F.E.BT
Device
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Lexington, Kentucky • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jul 21, 2026, 9:30 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor

NCT04796285
View directory record Official record
Conditions
Sepsis, Sepsis Bacterial, Lactate Blood Increase, Infectious Disease
Interventions
Lab Clasp
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Multicenter Blood Culture Quality Improvement

NCT01413555
View directory record Official record
Conditions
Bacteremia
Interventions
Blood Culture QI Program
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
14,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)

NCT00235690
View directory record Official record
Conditions
Bacteremia, Pseudomonas Infections
Interventions
Blood draws, Blood draw
Procedure · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial

NCT04620486
View directory record Official record
Conditions
Infections, Bacterial, Sepsis, Alert Fatigue, Health Personnel
Interventions
Epic Best Practice Alert
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01817075
View directory record Official record
Conditions
Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection, Myeloid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Months to 21 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
53
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Voriconazole to Prevent Systemic Fungal Infections in Children

NCT00005912
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

NCT00739934
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
voriconazole (Vfend)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Jul 21, 2026, 9:30 PM EDT